Dose Optimization of Recombinant Factor VIIa for Control of Mild to Moderate Bleeds in Inhibitor Patients: Improved Efficacy with Higher Dosing

Seminars in Hematology

Volumn 41, Issue 1 SUPPL. 1, 2004, Pages 3-7

  Abshire, Thomas C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD CLOTTING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; EXPERIENCE; FIBRIN CLOT; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HUMAN; IN VITRO STUDY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE MEMBRANE; TREATMENT INDICATION;

EID: 0842320983     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2003.11.002     Document Type: Conference Paper

References (24)

1. Allen GA, Monroe DM 3rd, Roberts HR, et al: The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation. Blood Coagul Fibrinolysis 11:S3-7, 2000 (suppl)
2. Allen GA, Hoffman M, Roberts HR, et al: Recombinant activated factor VII: Its mechanism of action and role in the control of hemorrhage. Can J Anaesth 49:S7-14, 2002 (suppl)
3. Blomback B, Carlsson K, Fatah K, et al: Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75:521-538, 1994
4. Cooper HA, Jones CP, Campion E, et al: Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 7:517-522, 2001
5. Erhardtsen E: Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 26:385-391, 2000
6. Hedner U: Recombinant factor VIIa (NovoSeven) as a hemostatic agent. Dis Mon 49:39-48, 2003
7. Hoffman M, Monroe DM, Roberts HR: Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9:S61-65, 1998 (suppl)
8. Ingerslev J, Thykjaer H, Kudsk Jensen O, et al: Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis 9:S107-110, 1998 (suppl)
9. Kenet G, Lubetsky A, Luboshitz J, et al: A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 1:450-455, 2003
10. Key NS, Aledort LM, Beardsley D, et al: Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 80:912-918, 1998
11. Laurian Y, Goudemand J, Negrier C, et al: Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 9:S155-156, 1998 (suppl)
12. Lindley CM, Sawyer WT, Macik BG, et al: Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55:638-648, 1994
13. Lisman T, Mosnier LO, Lambert T, et al: Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 99:175-179, 2002
14. Lusher JM, Roberts HR, Davignon G, et al: A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors (rFVIIa study group). Haemophilia 4:790-798, 1998
15. Lusher JM: Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 11:S45-49, 2000 (suppl)
16. Martinowitz U: The use of rFVIIa as an adjunct treatment for hemorrhage control in trauma and surgery. Bloodline Rev 1:9-11, 2001
17. Meijers JCM: Regulation of coagulation: The role of TAFI. Presented at the XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK, July 12-18, 2003
18. Monroe DM, Hoffman M, Oliver JA, et al: Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 99:542-547, 1997
19. Negrier C, Hay CR: The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 26:407-412, 2000
20. Parameswaran R, Shapiro AD, Cox Gill J, et al: Dose effect and efficacy of recombinant factor VIIa (rFVIIa) in the treatment of hemophilia patients with inhibitors: Analysis from the Hemophilia Research Society (HRS) Registry. Blood 100:22a, 2002 (abstr)
21. Santagostino E, Gringeri A, Mannucci PM: Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 104:22-26, 1999
22. Scharrer I: Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 5:253-259, 1999
23. Shapiro AD, Gilchrist GS, Hoots WK, et al: Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80:773-778, 1998
24. Stewart AJ, Hanley JP, Ludlam CA: Safety, efficacy and cost effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 9:S9395, 1998 (suppl)